Brian P Rutledge

Dr. Brian P Rutledge

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in Case Reports in Gastroenterology
Verified
Journal Article
Open access
PDF file
BRBrian P Rutledge
Brian P Rutledge
ADAnupama Devara
Anupama Devara
SBSindhuri Benjaram
Sindhuri Benjaram
SJStephanie Judd
Stephanie Judd
MEMurray Ehrinpreis
Murray Ehrinpreis
The Fontan circulation alters a patient’s physiology and imparts long-term risks related to chronically elevated systemic venous pressure. An increasing number of patients with Fontan physiology are surviving into adulthood and are at risk of hepatic sequalae. The ideal timeline and method of hepatic surveillance in the Fontan population remains to be defined. In this case, the patient was diagnosed with hepatocellular carcinoma more than 20 years after undergoing the Fontan procedure and was a candidate for combined heart-liver transplant. That her disease progressed prior to organ availability supports the argument for hepatic surveillance in this population.

1 January 2021 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
ESEric M Sieloff
Eric M Sieloff
BRBrian P Rutledge
Brian P Rutledge
CHCuyler Huffman
Cuyler Huffman
DVDuncan Vos
Duncan Vos
TMThomas Melgar
Thomas Melgar
Background: Medical literature on the prevalence of genetic liver disease is lacking. In this study, we investigated the in-hospital healthcare and economic burden from genetic causes of non-alcoholic chronic liver disease (NACLD) and non-alcoholic liver cirrhosis (NALC) in the USA. Methods: Data were abstracted from the National Inpatient Sample database between 2002 and 2014 using ICD9 codes for patients discharged with NACLD and NALC secondary to genetic diseases including alpha-1 antitrypsin deficiency (A1ATd), cystic fibrosis (CF), Wilson disease (WD), hereditary hemochromatosis (HHC), glycogen storage disease, and disorders of aromatic amino-acid metabolism (DAAAM). Results: Throughout the study period, there were 19,332 discharges for NACLD associated with the six genetic diseases including 14,368 for NALC. There were $1.09 billion in hospital charges, 790 in-hospital deaths, and 955 liver transplants performed. Overall, A1ATd was associated with 8,983 (62.52%) hospitalizations for NALC followed by WD, CF, and HHC. The highest in-hospital mortality was seen with HHC. The greatest frequency of liver transplants was seen with DAAAM. Conclusion: The number of hospitalizations for genetic liver diseases continues to increase. With increased funding and directed research efforts, we can aim to improve medical treatments and the quality of life for patients at risk for liver deterioration.

8 July 2024 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MIMohamad Itani
Mohamad Itani
BFBassem Farah
Bassem Farah
MWMargaret Wasvary
Margaret Wasvary
AWAnshu Wadehra
Anshu Wadehra
TWTj Wilson
Tj Wilson
MMMilton Mutchnick
Milton Mutchnick

25 July 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
ASAstha Saini
Astha Saini
BRBrian P Rutledge
Brian P Rutledge
ADAnirudh Damughatla
Anirudh Damughatla
MRMina Saad Rasheed
Mina Saad Rasheed
PNP.aul H Naylor
P.aul H Naylor
MMMilton Mutchnick
Milton Mutchnick
African Americans (AA) have a high incidence of risk factors associated with MASLD (metabolic dysfunction-associated steatotic liver disease); the AA population has a lower incidence of MASLD and MASH (metabolic-associated steatotic hepatitis) than Caucasian and Hispanic Americans (non-AA). We investigated if underlying risk factor variation between AA and non-AA individuals could provide a rationale for the racial diversity seen in MASLD/MASH. Using ICD-10 codes, patients from 2017 to 2020 with MASLD/MASH were identified and confirmed to have either MASLD or MASH. Despite the large (>80%) AA population in our clinics, only 54% of the MASLD/MASH patients were African American. When the non-invasive NAFLD Fibrosis Scores (NFS) evaluated at early diagnosis were compared to the most recent values, the only increase in fibrosis score by NFS over time was in non-AA MASH patients. The increase in fibrosis only in non-AA MASLD patients is consistent with racial disparity in the disease progression in non-AA as compared to AA patients. Even with the large proportion of AA patients in our study, there was no significant racial disparity in the earliest assessment of either risk factors, laboratory values, or fibrosis scores that would account for racial disparity in the development and progression of MASLD.

28 December 2018 in Journal of Gastroenterology and Hepatology Research
Verified
Journal Article
Open access
PDF file
BRBrian P Rutledge
Brian P Rutledge
VMVipul Mahajan
Vipul Mahajan
PNPaul Naylor
Paul Naylor
SBSindhuri Benjaram
Sindhuri Benjaram
MEMurray Ehrinpreis
Murray Ehrinpreis
MMMilton Mutchnick
Milton Mutchnick
Similarities in Hepatitis C Patient Profiles Over a Decade in an Urban GI Clinic

2 December 2019 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
BRBrian P Rutledge
Brian P Rutledge
JJJenny Jan
Jenny Jan
SBSindhuri Benjaram
Sindhuri Benjaram
NSNeha Sahni
Neha Sahni
PNPaul Naylor
Paul Naylor
MMMilton Mutchnick
Milton Mutchnick